Observational studyMedicine2025
Exploring the impact of dietary theobromine on endometriosis risk: Evidence from Mendelian randomization and NHANES data.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a chronic inflammatory estrogen-dependent inflammatory disorder. Theobromine has been implicated in diverse health benefits, including anti-inflammatory and vasodilatory properties. However, the precise association between theobromine and endometriosis remains largely undetermined. To address this gap, this study sought to explore the causal relationship between theobromine exposure and the risk of endometriosis by leveraging Mendelian randomization (MR) and data from the National Health and Nutrition Examination Survey (NHANES). This study included 244 participants from the NHANES (1999-2004). Multivariable logistic regression (adjusted for age, body mass index, smoking, alcohol intake, and energy intake) assessed associations between dietary theobromine intake and endometriosis diagnosis age. Two-sample MR (16,588 cases/1,11,583 controls) used 12 theobromine-associated single-nucleotide polymorphisms (P < 5 × 10⁻⁸) as instruments, with inverse variance weighted analysis. MR assumptions were verified via F-statistics (>10), heterogeneity (Cochran's Q P > .05), and pleiotropy (MR-Egger P > .05). In the observational study (NHANES), each 1 μg/d increment in dietary theobromine intake was associated with a 1.49-year delay in endometriosis diagnosis age (β = 1.49, 95% CI: 0.02-2.95, P = .048) after multivariable adjustment. In the MR analysis, the inverse variance weighted method showed a significant causal effect estimate of β = -0.1057 (95% CI: -0.2098 to -0.0016, P = .045) for the effect of theobromine on endometriosis risk. Sensitivity analyses confirmed robustness against pleiotropy and heterogeneity. This study suggests a potential causal relationship between dietary theobromine intake and a modestly reduced risk of endometriosis, providing preliminary insights into the potential protective effects of theobromine against the development of this condition. However, further investigations are necessary to validate these findings and to understand the underlying biological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.